CLINICAL STUDIES OF T-3262 IN RESPIRATORY INFECTION

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement9-Clinical; pp. 413 - 417
• Main Authors: KAWAI, TAKESHI, TOYODA, TAKEO, ONAKA, AKIO
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 20.12.1988
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement9-Clinical_413

We clinically evaluated T-3262, a pyridone-carboxylic acid derivative, in respiratory infection. The subjects were 12 cases: bronchopneumonia 4, diffuse panbronchiolitis 3, acute bronchitis 2 and 1 each of acute exacerbation of chronic bronchitis, bacterial pyothorax and pharyngitis. Causative organisms were 3 strains of Pseudomonas aeruginosa, 2 of Haemophilus influenzae, one each of Streptococcus pneumoniae, Streptococcus aureus, Klebsiella sp., Haemophilus parainfluenzae, Acinetobacter and Enterobacter cloacae. Two cases were superinfected and three were found with normal flora. The daily dose was 450-900 mg, and the duration of the trial was 7-42 days (mean, 20.6 days). The total dose was 3.15-21.0g and the mean was 11.7g. The bacteriological results were eradication in 5 cases, colonization in 1, and persistent infection in 2 of diffuse panbronchiolitis due to P. aeruginosa. Clinical efficacy was excellent in 2 cases (16.7%), good in 5 (41.7%), fair in 2 (16.7%) and poor in 3 (25.0%). Vomiting and upper abdominal pain was observed in one case each. For evaluation of drug transfer to sputum, 300 mg of T-3262 was administered to 2 cases of diffuse panbronchiolitis. Maximum sputum concentration was observed at 3 or 6 h at a concentration of 0.25 or 0.16μg/ml, which was 30% or 42% of that in serum. Our data showed that transfer of T-3262 into sputum was relatively good.